- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
What We are Reading: A Pioneer in GLP-1 Research Fights for Recognition
Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
Svetlana Mojsov, Ph.D., is a researcher who, early in her career, was influential part of the team of researchers at Massachusetts General Hospital who discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss. Their work and the paper, where she was lead author, eventually led to the development of the blockbuster drugs Victoza, Ozempic and Mounjaro.
But somewhere along the way, Mojsov’s role had been minimized and she didn’t receive awards and recognition that that her colleagues did and was even left off several patents on the research. Several recent articles are working to correct the record, including one in Science and on Stat.
